Press reports on our research

Liz Brody guides Oprah readers through psychedelics' benefits and risks 

As access grows, we need better research and education on bad trips, writes Oshan Jarrow 

 AWhile much has been made about the power of these drugs to treat pernicious mental health issues, what gets lost are the people who get hurt in the process, writes Katie McBride

Article by Ed Prideaux on our and his research on HPPD

NBC News coverage of our extended difficulties paper

Coverage of our extended difficulties paper in the UK's most popular newspaper

Simon Doherty interviewed Jules Evans for this feature on psychedelic harms and risks 

Floris Wolswijk interviewed Anna Lutkajtis and myself on our study of integration challenges after a psychedelic retreat. 

Psychedelic therapy is becoming increasingly popular, and has been tried by Prince Harry. But we need to learn more about risks and how to manage them, writes John Naish

 An interview with Jules Evans for UC Berkeley's Microdose newsletter

 Before psychedelic therapy and services becomes widely available, there needs to be a better understanding of all the ways these experiences can go wrong, writes Shayla Love

Shruti Ravindran profiles Jules Evans and the Challenging Psychedelic Experiences Project

New research suggests that a significant proportion of users faces long-term difficulties following psychedelic experiences, including emotional and social challenges and perceptual problems, writes Mo Costandi

Alexandra Jones says the risks and harms of psychedelics require more research before health systems introduce these new treatments

As psychedelic therapy trials get bigger and the drugs become more accessible, researchers need to start talking about their potential adverse effects., writes Grace Browne

 Regulators face new challenges over whether - and how - to allow people to access mind-altering drugs to treat mental health conditions, writes Helen Collis.

Psychedelic companies and investors should invest to learn about and protect people from the risks of psychedelic therapy writes Jules Evans